CD8A and ovarian carcinoma: Administration of Exoblock in vivo against an ovarian tumor-based omental tumor xenograft model and a melanoma-based xenomimetic (X-) mouse model reduces phosphatidylserine positive exosomes and increases the amount and function of CD4 and CD8 T cells leading to the suppression of tumor recurrence of melanoma and progression and metastasis of ovarian cancer [207].